Trajan Group Holdings Ltd (AU:TRJ)
ASX:TRJ
Top Page
Trajan Group Holdings Ltd
(Sydney:TRJ)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.39
▼(-1.50% Downside)
Action:ReiteratedDate:03/20/26
The score is primarily constrained by weak technicals (price below all key moving averages, negative MACD) and profitability/cash-flow challenges (net losses and falling free cash flow). Moderate revenue growth and a relatively stable balance sheet partially offset these risks, but valuation support is limited given negative earnings and no stated dividend.
Positive Factors
Recurring consumables revenue
Trajan's core business sells laboratory consumables that are repurchased routinely. This creates a stable, repeatable revenue base and higher visibility into mid-term sales, supporting cash generation and enabling cross-sell into pharma, clinical and environmental lab workflows over 2–6 months.
Negative Factors
Ongoing net losses
Persistent net losses and negative return on equity signal the business is not yet generating sustainable profits. Over months this constrains reinvestment from earnings, may require external funding for growth, and limits the firm's ability to self-fund margin-improvement initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables revenue
Trajan's core business sells laboratory consumables that are repurchased routinely. This creates a stable, repeatable revenue base and higher visibility into mid-term sales, supporting cash generation and enabling cross-sell into pharma, clinical and environmental lab workflows over 2–6 months.
Read all positive factors
Trajan Group Holdings Ltd (TRJ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$61.04M
Dividend YieldN/A
Average Volume (3M)21.61K
Price to Earnings (P/E)―
Beta (1Y)0.46
Revenue Growth7.38%
EPS Growth82.39%
CountryAU
Employees600
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)<0.01
Shares Outstanding152,593,050
10 Day Avg. Volume15,523
30 Day Avg. Volume21,606
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)1.03
Price to Sales (P/S)0.65
P/FCF Ratio16.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.03Price Target Upside157.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.03
Revenue Forecast (FY)AU$172.83M
Trajan Group Holdings Ltd Business Overview & Revenue Model
Company Description
Trajan Group Holdings Limited develops, manufactures, sells, and distributes analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India. The company op...
How the Company Makes Money
TRJ primarily makes money by selling laboratory consumables and related products into analytical testing and research markets. Its core revenue streams typically include: (1) recurring sales of consumables (e.g., chromatography consumables, sample...
Trajan Group Holdings Ltd Financial Statement Overview
Summary
Income Statement
55
Neutral
Balance Sheet
60
Neutral
Cash Flow
50
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 169.52M | 166.46M | 155.02M | 162.15M | 107.57M | 76.57M |
| Gross Profit | 42.31M | 63.47M | 59.75M | 22.93M | 42.63M | 28.48M |
| EBITDA | 6.69M | 8.14M | -20.36M | 14.16M | 5.14M | 3.46M |
| Net Income | -1.38M | -4.46M | -25.33M | 1.89M | 1.70M | 1.88M |
Balance Sheet | ||||||
| Total Assets | 192.32M | 195.63M | 188.00M | 229.04M | 206.78M | 99.38M |
| Cash, Cash Equivalents and Short-Term Investments | 12.78M | 11.85M | 11.24M | 11.04M | 13.16M | 51.72M |
| Total Debt | 69.37M | 55.49M | 56.16M | 61.30M | 66.18M | 17.02M |
| Total Liabilities | 89.27M | 90.01M | 85.15M | 99.51M | 90.27M | 33.30M |
| Stockholders Equity | 103.05M | 105.62M | 102.85M | 129.53M | 116.51M | 66.08M |
Cash Flow | ||||||
| Free Cash Flow | 1.46M | 6.74M | 6.43M | 998.00K | -1.28M | 8.34M |
| Operating Cash Flow | 4.47M | 10.83M | 9.47M | 9.55M | 2.13M | 9.45M |
| Investing Cash Flow | -3.02M | -4.09M | -3.04M | -8.55M | -116.38M | 402.00K |
| Financing Cash Flow | 1.57M | -5.64M | -6.40M | -3.36M | 74.69M | 36.81M |
Trajan Group Holdings Ltd Technical Analysis
Negative
0.40
Price Trends
0.56
Negative
0.62
Negative
0.71
Negative
Market Momentum
-0.05
Positive
26.20
Positive
19.23
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRJ, the sentiment is Negative. The current price of 0.4 is below the 20-day moving average (MA) of 0.46, below the 50-day MA of 0.56, and below the 200-day MA of 0.71, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 26.20 is Positive, neither overbought nor oversold. The STOCH value of 19.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:TRJ.
Trajan Group Holdings Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | AU$131.16M | 7.70 | 14.03% | ― | 39.98% | -30.04% | |
57 Neutral | AU$38.10M | -25.86 | 10.35% | 2.81% | 0.65% | -9.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$61.04M | -59.43 | -1.32% | ― | 7.38% | 82.39% | |
44 Neutral | AU$102.68M | -6.27 | -54.48% | ― | 34.20% | -23.90% | |
43 Neutral | AU$75.76M | -6.64 | -59.96% | ― | ― | ― | |
42 Neutral | AU$84.50M | -14.80 | -40.65% | ― | 700.00% | 26.88% |
* Healthcare Sector Average
AU:TRJ
Trajan Group Holdings Ltd
0.40
-0.43
-51.81%
AU:AHC
Austco Healthcare Limited
0.35
0.06
20.69%
AU:CYC
Cyclopharm Limited
0.85
-0.42
-33.33%
AU:SHG
Singular Health Group Ltd
0.24
<0.01
2.13%
AU:EZZ
EZZ Life Science Holdings Ltd.
0.81
-0.64
-44.29%
AU:ALA
Arovella Therapeutics Limited
0.07
-0.01
-15.66%
Trajan Group Holdings Ltd Corporate Events
Trajan issues 53,022 new shares in routine capital management move
Mar 31, 2026
Trajan Group Holdings has issued 53,022 ordinary fully paid shares on 27 March 2026 and notified the market that this capital issuance was conducted without a prospectus under the disclosure exemptions in the Corporations Act. The company confirme...
Trajan Seeks ASX Quotation for Additional Ordinary Shares
Mar 31, 2026
Trajan Group Holdings has applied for quotation on the ASX of 53,022 new ordinary fully paid shares under its ticker TRJ, with an issue date of 27 March 2026. The additional stock arises from the conversion or exercise of existing options or other...
Trajan Defends Fundamentals and Reaffirms Outlook Amid Share Price Slide
Mar 27, 2026
Global analytical science and device company Trajan Group Holdings has moved to reassure shareholders following a recent decline in its share price, stating there is no known fundamental business issue behind the drop and that it remains on track ...
Trajan CFO Alister Hodges to Step Down After 15 Years of Service
Mar 24, 2026
Trajan Group Holdings has announced the resignation of Chief Financial Officer and Joint Company Secretary Alister Hodges, who will leave the company on 11 November 2026 after more than 15 years of service. The board has launched a formal executiv...
Trajan Narrowly Reduces Half-Year Loss Despite Modest Revenue Growth
Feb 25, 2026
Trajan Group Holdings Limited reported a 3.8% increase in revenue to $84.1 million for the half-year ended 31 December 2025, but recorded a net loss after tax attributable to shareholders of $0.4 million, an 87.5% improvement in the loss position ...
Trajan Holds FY26 Guidance as Q2 Rebound Offsets Soft Start
Feb 5, 2026
Trajan Group Holdings has reaffirmed its full-year FY26 guidance despite a softer first quarter that weighed on half-year earnings, reporting expected group net revenue growth of 3.8% to $84.1 million for the first half and a decline in normalised...
Trajan Sets Date for FY26 Half-Year Results and Investor Webcast
Jan 29, 2026
Trajan Group Holdings Limited has announced that it will release its financial results for the first half of the 2026 financial year, covering the period ending 30 June 2026, on 26 February 2026. The company will host a live investor webcast and Q...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.